A Study of Pumitamig Compared to Pembrolizumab in People With Non-Small Cell Lung Cancer (NSCLC)

Full Title

Rosetta-Lung 202: A Randomized, Double-Blind, Phase 3 Study of Pumitamig Monotherapy Compared to Pembrolizumab as First-line Treatment in Participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with PD-L1 >= 50%.

Purpose

To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.

Contact

For more information or to see if you can join this study, please call Dr. Mark Awad’s office at 646-607-4371.

Protocol
26-265
Phase
Phase III (phase 3)
Investigator
Mark Awad
Co-Investigators
Adam J. Schoenfeld
Diseases
Lung Cancer › Lung Cancer, Non-Small Cell
Locations
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Commack Nonna’s Garden Foundation Center
Memorial Sloan Kettering Basking Ridge
Memorial Sloan Kettering Westchester
Memorial Sloan Kettering Monmouth
Memorial Sloan Kettering Bergen
Memorial Sloan Kettering Nassau
ClinicalTrials.gov ID
NCT07361510
ClinicalTrials.gov
Visit ClinicalTrials.gov for full clinical trial description